Skip to main content
Skip to main content
MHUA logo

Meihua International Medical Technologies Co., Ltd. (MHUA) Stock Analysis

$7.61 -$1.26 (-14.21%) |CouncilSplit View · 52 · B
Signals are mixed — the Council read leans Split View (52/100) while the AI fundamental score is 38/100 (grade D); the two lenses disagree, so weigh the breakdown below. Strongest signal: Seth Klarman bullish · Biggest watch-out: Jim Simons bearish.
MCap: $2.41M| Vol: 1.0K|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Meihua International Medical Technologies Co., Ltd. (MHUA) trades at $7.61 with AI Score 38/100 (Grade D). Meihua International Medical Technologies Co. , Ltd. manufactures and markets medical consumables, including disposable medical devices, primarily in China. Market cap: $2.41M, Sector: Healthcare.

Price as of Jul 20, 2026 · Last analyzed: Mar 17, 2026
Meihua International Medical Technologies Co., Ltd. manufactures and markets medical consumables, including disposable medical devices, primarily in China. The company also exports its products globally, serving hospitals, pharmacies, and medical institutions.

Analyst Coverage for MHUA: MHUA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MHUA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Watch the MHUA film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Split View 52/100 · B

MHUA: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Jim Simons
Bearish
Izzy Englander
Bullish
Seth Klarman
Bullish
Moon AI
Bullish
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Moderate
Margin of Safety
Undervalued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Meihua International Medical Technologies Co., Ltd. (MHUA) Healthcare & Pipeline Overview

CEOLee Leyi
Employees619
HeadquartersYangzhou, CN
IPO Year2022

Meihua International Medical Technologies Co., Ltd. focuses on manufacturing and distributing class I, II, and III disposable medical devices within China and internationally. With a P/E ratio of 0.30 and a profit margin of 10.4%, the company serves hospitals, pharmacies, and medical institutions, offering both self-manufactured and sourced products.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 17, 2026

What Is the Investment Thesis for MHUA?

As of Mar 17, 2026 — figures reflect the data available on that date.

Meihua International Medical Technologies Co., Ltd. presents a focused investment opportunity within the medical consumables market. The company's low P/E ratio of 0.30 suggests potential undervaluation, while a profit margin of 10.4% indicates profitability. Growth catalysts include expanding its distribution network within China and increasing exports to other regions. The company's ability to offer both manufactured and distributed products provides flexibility and scalability. Key risks include competition from established medical device manufacturers and potential regulatory changes in the healthcare sector. Investors should monitor the company's ability to maintain its profit margins and expand its market share in a competitive environment.

Based on FMP financials and quantitative analysis

MHUA Key Highlights

  • P/E ratio of 0.30, indicating potential undervaluation compared to industry peers.
  • Profit margin of 10.4%, demonstrating the company's ability to generate profits from its operations.
  • Gross margin of 34.2%, reflecting the efficiency of its manufacturing and distribution processes.
  • Beta of 0.75, suggesting lower volatility compared to the overall market.
  • Exports to multiple continents, including Europe, North America, and Asia, showcasing a diversified geographic reach.

Who Are MHUA's Competitors?

MHUA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
BFRI Biofrontera Inc. $1.05 -3.67% $13.4M
NSTG NanoString Technologies, Inc. $0.11 -37.43% $5.07M 51
BLMHF Bloom Health Partners Inc. $0.11 +0.00% $5.22M 51
ZTEK Zentek Ltd. $0.46 -2.13% $49.5M 63
OMIC Singular Genomics Systems, Inc. $20.01 +0.00% $50.8M 61
DXR Daxor Corporation $10.91 +0.05% $55.0M 58
NYXH Nyxoah S.A. $1.56 -0.64% $61.8M 69
PDEX Pro-Dex, Inc. $54.66 -4.74% $175M 81

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are MHUA's Key Strengths?

  • Established manufacturing capabilities in China.
  • Diverse product portfolio of class I, II, and III medical devices.
  • Distribution network covering both domestic and international markets.
  • Ability to offer both self-manufactured and distributed products.

What Are MHUA's Weaknesses?

  • Reliance on the Chinese market.
  • Limited brand recognition compared to larger competitors.
  • Potential vulnerability to regulatory changes in the healthcare sector.
  • Smaller scale of operations compared to multinational corporations.

What Could Drive MHUA Stock Higher?

  • Expansion of distribution network within China to reach more hospitals and medical institutions.
  • Increasing exports to new international markets, diversifying revenue streams.
  • Potential new product launches in the disposable medical device market.
  • Strategic partnerships with other medical device companies to expand product offerings and market reach.

What Are the Key Risks for MHUA?

  • Intense competition from established medical device manufacturers.
  • Changes in government regulations or healthcare policies affecting the medical device industry.
  • Risk of product recalls or liability claims related to medical devices.
  • Reliance on the Chinese market, exposing the company to economic fluctuations in China.

What Are the Growth Opportunities for MHUA?

  • Expanding product offerings within the disposable medical device market represents a significant growth opportunity. By introducing new and innovative products, Meihua can attract a wider customer base and increase its market share. The global disposable medical device market is projected to reach $48.9 billion by 2027, growing at a CAGR of 8.2% from 2020. This growth is driven by increasing healthcare expenditure and rising awareness of infection control. Timeline: 2-3 years.
  • Increasing its distribution network within China presents another key growth opportunity. By partnering with more hospitals, pharmacies, and medical institutions, Meihua can expand its reach and increase sales. China's healthcare market is one of the largest and fastest-growing in the world, driven by a large population and increasing healthcare spending. The Chinese medical device market is expected to reach $124.5 billion by 2027. Timeline: 1-2 years.
  • Expanding its export markets beyond its current reach offers substantial growth potential. By targeting new regions and countries, Meihua can diversify its revenue streams and reduce its reliance on the Chinese market. The global medical device market is projected to reach $603.4 billion by 2028, growing at a CAGR of 5.4% from 2021. This growth is driven by technological advancements and increasing demand for medical devices in emerging markets. Timeline: 3-5 years.
  • Developing strategic partnerships with other medical device companies can provide access to new technologies and markets. By collaborating with companies that have complementary products or expertise, Meihua can enhance its competitive position and accelerate its growth. Strategic alliances can provide access to new distribution channels, research and development capabilities, and manufacturing efficiencies. Timeline: 2-3 years.
  • Investing in research and development to create innovative medical consumables can drive long-term growth. By developing new products that address unmet needs in the healthcare market, Meihua can differentiate itself from its competitors and capture a larger market share. Innovation is crucial in the medical device industry, as new technologies and products can significantly improve patient outcomes and reduce healthcare costs. Timeline: 3-5 years.

What Opportunities Does MHUA Have?

  • Expanding product offerings within the disposable medical device market.
  • Increasing its distribution network within China.
  • Expanding its export markets to new regions and countries.
  • Developing strategic partnerships with other medical device companies.

What Threats Does MHUA Face?

  • Intense competition from established medical device manufacturers.
  • Potential for price erosion due to competitive pressures.
  • Risk of product recalls or liability claims.
  • Changes in government regulations or healthcare policies.

What Are MHUA's Competitive Advantages?

  • Established manufacturing capabilities for disposable medical devices.
  • Distribution network within China and internationally.
  • Ability to offer both manufactured and distributed products.
  • Long-standing relationships with hospitals, pharmacies, and medical institutions.

What Does MHUA Do?

Founded in 1991 and based in Yangzhou, China, Meihua International Medical Technologies Co., Ltd. specializes in the production and distribution of medical consumables. The company offers a range of class I, II, and III disposable medical devices, catering to the needs of hospitals, pharmacies, medical institutions, and medical equipment companies. Meihua's product portfolio includes both non-bottled items like brushes and ID bracelets, as well as polyethylene bottled products such as eye drop and tablet bottles. In addition to its own manufactured products, Meihua also distributes disposable medical devices sourced from other manufacturers, expanding its offerings to meet diverse customer demands. The company's market reach extends beyond China, with exports to Europe, North America, South America, Asia, Africa, and Oceania. Operating as a subsidiary of Bright Accomplish Limited, Meihua International Medical Technologies Co., Ltd. has established itself as a key player in the medical consumables market, focusing on providing essential medical supplies to a broad range of healthcare providers and institutions worldwide.

What Products and Services Does MHUA Offer?

  • Manufactures class I, II, and III disposable medical devices.
  • Offers non-bottled products like brushes and ID bracelets.
  • Produces polyethylene bottled products such as eye drop and tablet bottles.
  • Distributes disposable medical devices sourced from other manufacturers.
  • Serves hospitals, pharmacies, medical institutions, and medical equipment companies.
  • Exports products to Europe, North America, South America, Asia, Africa, and Oceania.

How Does MHUA Make Money?

  • Manufacturing and selling its own line of disposable medical devices.
  • Distributing medical devices sourced from other manufacturers.
  • Generating revenue through sales to hospitals, pharmacies, and medical institutions.
  • Exporting products to international markets.

What Industry Does MHUA Operate In?

Meihua International Medical Technologies Co., Ltd. operates within the medical instruments and supplies industry, a sector characterized by consistent demand driven by healthcare needs. The industry is competitive, with numerous players ranging from large multinational corporations to smaller specialized manufacturers. Market trends include increasing demand for disposable medical devices due to heightened hygiene standards and a growing aging population. Meihua's focus on both manufacturing and distributing medical consumables positions it to capitalize on these trends, although it faces competition from established companies with greater resources and brand recognition.

Who Are MHUA's Key Customers?

  • Hospitals
  • Pharmacies
  • Medical institutions
  • Medical equipment companies
AI Confidence: 72% Updated: Mar 17, 2026

F-Score 4/9Financial Health

Meihua International Medical Technologies Co., Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.11 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 4%Key Financial Metrics

Return on equity for Meihua International Medical Technologies Co., Ltd. stands at 3.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.3%, showing how much profit it generates from its asset base. MHUA trades at a trailing price-to-earnings ratio of 0.92, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 108.3%, the inverse of the P/E and a quick read on earnings relative to price.

MHUA Valuation & Market Position

With a $2.41M market cap, Meihua International Medical Technologies Co., Ltd. sits in the micro-cap segment of the market. Relative to its peer group, MHUA's quantitative score of 38/100 is below the peer average of 57/100.

MHUA Financials

Fundamental Snapshot

Revenue Growth (FY)
-0.2%
Net Income Growth (FY)
-6.7%
EPS Growth (FY)
-18.4%
P/E (TTM)
0.9
Return on Equity (TTM)
+3.8%
Current Ratio
8.4

Based on FMP financials and quantitative analysis · FY 2024

Bull Case vs Bear Case

Bull Case

  • Established manufacturing capabilities in China.
  • Diverse product portfolio of class I, II, and III medical devices.
  • Distribution network covering both domestic and international markets.
  • Ability to offer both self-manufactured and distributed products.

Bear Case

  • Reliance on the Chinese market.
  • Limited brand recognition compared to larger competitors.
  • Potential vulnerability to regulatory changes in the healthcare sector.
  • Smaller scale of operations compared to multinational corporations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026

MHUA Latest News

MHUA Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MHUA.

Price Targets

Wall Street price target analysis for MHUA.

MHUA MoonshotScore

38/100

What does this score mean?

The MoonshotScore rates MHUA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: Lee Leyi

CEO

Lee Leyi serves as the CEO of Meihua International Medical Technologies Co., Ltd. Details regarding Lee Leyi's specific educational background and prior professional experiences are not available in the provided data. However, as CEO, Lee Leyi is responsible for the overall strategic direction and operational management of the company, overseeing the manufacturing, distribution, and marketing of medical consumables.

Track Record: Under Lee Leyi's leadership, Meihua International Medical Technologies Co., Ltd. has focused on expanding its product offerings and distribution network. Specific achievements and milestones under Lee Leyi's tenure are not detailed in the provided data, but the company's continued operation and market presence suggest a commitment to growth and stability within the medical consumables sector.

What Investors Ask About Meihua International Medical Technologies Co., Ltd. (MHUA) — Healthcare

What does the AI Score mean for MHUA?

MHUA holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Meihua International Medical Technologies Co., Ltd. manufactures and markets medical consumables, including disposable medical devices, primarily in China. The company also exports its products …

What does Meihua International Medical Technologies Co., Ltd. do?

Meihua International Medical Technologies Co., Ltd. is a manufacturer and distributor of medical consumables, specializing in class I, II, and III disposable medical devices. The company produces a range of products, including non-bottled items like brushes and ID bracelets, as well as polyethylene bottled products such as eye drop and tablet bottles.

What are the main risks for MHUA?

Meihua International Medical Technologies Co., Ltd. faces several risks, including intense competition from established medical device manufacturers, potential changes in government regulations or healthcare policies, and the risk of product recalls or liability claims. The company's reliance on the Chinese market also exposes it to economic fluctuations in China. Additionally, the company's smaller scale of operations compared to multinational corporations may limit its ability to compete on price and innovation.

What are the key factors to evaluate for MHUA?

Meihua International Medical Technologies Co., Ltd. (MHUA) holds an AI score of 38/100 (low). Not financial advice.

How frequently does MHUA data refresh on this page?

MHUA's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven MHUA's recent stock price performance?

Meihua International Medical Technologies Co., Ltd. (MHUA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established manufacturing capabilities in China. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider MHUA overvalued or undervalued right now?

Meihua International Medical Technologies Co., Ltd. (MHUA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research MHUA before investing?

Before investing in Meihua International Medical Technologies Co., Ltd. (MHUA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding MHUA to a portfolio?

Key strength of Meihua International Medical Technologies Co., Ltd. (MHUA): Established manufacturing capabilities in China. Weigh rewards against risks and diversify. Not financial advice.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • AI analysis is pending, and analyst consensus is not currently available.
  • CEO background information is limited.
Data Sources

Popular Stocks